Collaborative Opportunities
Accelerator Funded Projects Available For Licensing:
- Abrogation of human CD59 function for immune cancer therapy
- Angiogenin loss-of-function mutations in Amyotrophic Lateral Sclerosis
- Antibacterial discovery using a chemical suppressor screen
- CARS endoscopy for biomedicine
- Clp protease as a novel target for antibiotics against tuberculosis
- Design and testing of a new approach to promote CNS axon regeneration
- Detection of glycated CD59 for the diagnosis of impaired glucose tolerance
- Development of antimicrobial agents targeting bacterial cell envelope biogenesis
- Development of atherapeutic antibody against diabetes and related matabolic diseases
- Development of broad spectrum antibiotics for new targets
- From sugar to fat: The IRE1a XBP1 signaling pathway regulates hepatic lipogenesis
- Microbial VKOR as an anti-infective target
- Natural product Avrainvillamide and its analogs as selective anticancer agents
- Novel small molecule inhibitors of Th17 cell development
- Platform technology for small molecule modulators of autophagy in cancer, neurodegenerative diseases and pancreatitis
- Potent OGT inhibitors for the treatment of cancer and diabetic complications
- Small molecule inhibitors of the deubiquitinating enzymes Usp14 and Uch37
- Small molecule modulators of the immuno-regulatory PD-1:PD-L pathway
- Small molecule viral entry inhibitors that target HIV
- Smoothened inhibitors for cancer therapy
- Using tolerogenic dendritic cells to treat autoimmune disorders
For more information on any of the above technologies, please contact OTD.